Sungho Bea/LinkedIn
Aug 2, 2025, 17:34
Oral Anticoagulation in VTE: Apixaban Safer and More Effective than Rivaroxaban or Warfarin
The Heart has published on X:
“Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Apixaban was asso with a lower risk of recurrent VTE and major bleeding compared to rivaroxaban and warfarin in pts initiating oral anticoagulant therapy.”
Title: Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Authors: Sungho Bea, PharmD, PhD; Geetha S. Iyer, PhD; Dae Hyun Kim, MD, MPH, ScD; Kueiyu Joshua Lin, MD, ScD, MPH; Yichi Zhang, MS; Heidi Zakoul, BS; Helen Tesfaye, PharmD, MSc; Katsiaryna Bykov, PharmD, ScD
Read the full article here.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
-
Dec 18, 2025, 13:55Laurent Bertoletti: BAT-VTE is One of 7 Projects Funded Under the EFFECT Trial Call!
-
Dec 18, 2025, 13:34Alexandru Stieber Explores VEXAS Syndrome